



Please be a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/649,952
Filing Date	August 28, 2003
First Named Inventor	Kenju MIURA
Group Art Unit	1646 1647
Examiner Name	Unassigned Brunner
Attorney Docket Number	58777.000013

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
Bob	U1	5,464,817	—	STOSSEL et al.	11-07-1995	—

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
Bob	F1	JP	05050603	—	Kozo	03-02-1993	Abstract	—
Bob	F2	JP	06269284A	—	Takehisa	09-27-1994	Abstract	—
—	F3	JP	08510998T2	—	—	11-19-1998	Abstract	—
Bob	F4	JP	10067662A	—	Muellner et al.	03-10-1998	Abstract	—
Bob	F5	JP	10087484A	—	Muellner et al.	04-07-1998	Abstract	—

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
—	P1	International Search Report - PCT/JP202/13862, pp. 1-2	—
Bob	P2	GILLETT, G.T. et al., "Mapping of human non-muscle type cofilin (CFL1) to chromosome 11q13 and muscle-type cofilin (CFL2) to chromosome 14", Ann. Hum. Genet. (1996), Vol. 60, pp. 201-211	—
Bob	P3	GÖTZE, KATHARINA S. et al., "gp130-Stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells", Experimental Hematology 29 (2001), pp. 822-832	—
Bob	P4	HUANG, ERIC et al., "The Hematopoietic Growth Factor KL Is Encoded by the SI Locus and Is the Ligand of the c-kit Receptor, the Gene Product of the W Locus", Cell (October 5, 1990), Vol. 63, pp. 225-233	—

Examiner Signature

Brigitte E. Brunner

Date Considered

6/1/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box

→



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/649,952	
(use as many sheets as necessary)			Filing Date	August 28, 2003	
Sheet	2	of	First Named Inventor	Kenju MIURA	
			Group Art Unit	1646	1647
			Examiner Name	Unassigned	Bunner
			Attorney Docket Number	58777.000013	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P5	IGAKU, JIKKEN, "Experimental Medicine", Experimental Medicine (March 28, 1994), Vol. 12, No. 3, pp. 45-51	
	P6	IGAKU, JIKKEN, Experimental Medicine (May 13, 1994), Vol. 12, No. 4, pp. 24-28	
Bob	P7	KAWASHIMA, ICHIRO et al., "CD34 ⁺ Human Marrow Cells That Express Low Levels of Kit Protein Are Enriched For Long-Term Marrow-Engrafting Cells", Blood (May 15, 1996), Vol. 87, No. 10, pp. 4136-4142	
	P8	KIMURA, TAKAFUMI et al., "Simultaneous Activation of Signals Through gp130, c-kit, and Interleukin-3 Receptor Promotes a Trilineage Blood Cell Production in the Absence of Terminally Acting Lineage-Specific Factors", Blood (December 15, 1997), Vol. 90, No. 12, pp. 4767-4778	
	P9	LYMAN PhD, STEWART D., "Biological effects and potential clinical applications of Flt3 ligand", Curr. Hematol. (1998), Vol 5, No. 3, pp. 192-196	
	P10	MOON, ANNE et al., "The ADF/Cofilin Proteins: Stimulus-responsive Modulators of Actin Dynamics", Molecular Biology of the Cell (November 1995), Vol. 6, pp. 1423-1431	
Bob	P11	MOORE, MALCOLM A. S., "Clinical Implications of Positive and Negative Hematopoietic Stem Cell Regulators", Blood (July 1, 1991), Vol. 78, No. 1, pp. 1-19, The Journal of The American Society of Hematology	
	P12	MORIYAMA, KENJI et al., "Molecular functions of cofilin which regulates reorganization of actin cytoskeleton", Seikagaku (1999), Vol. 71, No. 2, pp. 101-114, Department of Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.	
Bob	P13	NAKAHATA, TATSUTOSHI et al., "Role of glycoprotein 130 and c-Kit signaling in proliferation and differentiation of human hematopoietic progenitor cells", Cancer Chemother Pharmacol (1996), Vol. 38, (Suppl), pp. S64-S68	
	P14	OGAWA, K. et al., Coding sequence of human placenta Cofilin cDNA, Nucleic Acids Research (1990), Vol. 18, No. 23	
	P15	OGAWA, MAKIO, "Differentiation and Proliferation of Hematopoietic Stem Cells", Blood (June 1, 1993), Vol. 81, No. 11, pp. 2844-2853	
Bob	P16	PIACIBELLO, WANDA et al., "Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood," Blood (April 15, 1997), Vol. 89, No. 8, pp. 2644-2653, Rapid Communication	

Examiner Signature	Budget E. Bunner	Date Considered	6/1/05
--------------------	------------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450 Alexandria, VA 22313-1450



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	3	of	3	Examiner Name	Unassigned <i>Bunner</i>
				Attorney Docket Number	58777.000013

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>Bob</i>	P17	WILLIAMS, DOUGLAS E. et al., "Identification of a Ligand for the c-kit Proto-Oncogene," Cell (October 5, 1990), Vol. 63, pp. 167-174	—
<i>Bob</i>	P18	ZSEBO, KRISZTINA M. et al., "Identification, Purification, and Biological Characterization of Hematopoietic Stem Cell Factor from Buffalo Rat Liver-Conditioned Medium", Cell (October 5, 1990), Vol. 63, pp. 195-201	—
	P19		
	P20		
	P21		
	P22		
	P23		
	P24		
	P25		
	P26		
	P27		

Examiner Signature	<i>Bridget E. Bunner</i>	Date Considered	<i>6/11/05</i>
--------------------	--------------------------	-----------------	----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450 Alexandria, VA 22313-1450

